Altered receptor binding densities in experimental antiphospholipid syndrome despite only moderately enhanced autoantibody levels and absence of behavioral features

Immunobiology

Volumn 219, Issue 5, 2014, Pages 341-349

  Frauenknecht, Katrin ^a   Katzav, Aviva ^b   Grimm, Christina ^a   Chapman, Joab ^b   Sommer, Clemens J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiphospholipid antibody level; Antiphospholipid syndrome; Behavior; In vitro receptor autoradiography; Neurotransmitter receptor

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AUTOANTIBODY; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; PHOSPHOLIPID ANTIBODY; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR CHANGE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; FEMALE; GLIA; HIPPOCAMPUS; HYPERACTIVITY; IN VITRO STUDY; LIGAND BINDING; MOTOR CORTEX; MOUSE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEPTOR BINDING; STAIRCASE TEST; UPREGULATION;

5-HT(1A) RECEPTOR; ANTIPHOSPHOLIPID ANTIBODY LEVEL; ANTIPHOSPHOLIPID SYNDROME; BEHAVIOR; IN VITRO RECEPTOR AUTORADIOGRAPHY; NEUROTRANSMITTER RECEPTOR;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; MICE; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, NEUROTRANSMITTER;

EID: 84896400833     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2013.11.006     Document Type: Article

References (60)

1. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rahnama N.P., Nathanson N.M., Silva A.J. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 2003, 6:51-58.
2. Andreassi C., Zoli A., Riccio A., Scuderi F., Lombardi L., Altomonte L., Eboli M.L. Anticardiolipin antibodies in patients with primary antiphospholipid syndrome: a correlation between IgG titre and antibody-induced cell dysfunctions in neuronal cell cultures. Clin. Rheumatol. 2001, 20:314-318.
3. Arinuma Y., Yanagida T., Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008, 58:1130-1135.
4. Aronovich R., Gurwitz D., Kloog Y., Chapman J. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology 2005, 210:781-788.
5. Asherson R.A., Mercey D., Phillips G., Sheehan N., Gharavi A.E., Harris E.N., Hughes G.R. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann. Rheum. Dis. 1987, 46:605-611.
6. Bainbridge N.K., Koselke L.R., Jeon J., Bailey K.R., Wess J., Crawley J.N., Wrenn C.C. Learning and memory impairments in a congenic C57BL/6 strain of mice that lacks the M2 muscarinic acetylcholine receptor subtype. Behav. Brain Res. 2008, 190:50-58.
7. Bakimer R., Fishman P., Blank M., Sredni B., Djaldetti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J. Clin. Invest. 1992, 89:1558-1563.
8. Brey R.L., Chapman J., Levine S.R., Ruiz-Irastorza G., Derksen R.H., Khamashta M., Shoenfeld Y. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003, 12:508-513.
9. Cervera R., Khamashta M.A., Shoenfeld Y., Camps M.T., Jacobsen S., Kiss E., Zeher M.M., Tincani A., Kontopoulou-Griva I., Galeazzi M., Bellisai F., Meroni P.L., Derksen R.H., de Groot P.G., Gromnica-Ihle E., Baleva M., Mosca M., Bombardieri S., Houssiau F., Gris J.C., Quéré I., Hachulla E., Vasconcelos C., Roch B., Fernández-Nebro A., Piette J.C., Espinosa G., Bucciarelli S., Pisoni C.N., Bertolaccini M.L., Boffa M.C., Hughes G.R. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 2009, 68:1428-1432. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies).
10. Chapman J., Abu-Katash M., Inzelberg R., Yust I., Neufeld M.Y., Vardinon N., Treves T.A., Korczyn A.D. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J. Neurol. Sci. 2002, 203/204:81-84.
11. Cimaz R., Meroni P.L., Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006, 15:191-197.
12. de Laat B., Pengo V., Pabinger I., Musial J., Voskuyl A.E., Bultink I.E., Ruffatti A., Rozman B., Kveder T., de Moerloose P., Boehlen F., Rand J., Ulcova-Gallova Z., Mertens K., de Groot P.G. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J. Thromb. Haemost. 2009, 7:1767-1773.
13. Diederich K., Frauenknecht K., Minnerup J., Schneider B.K., Schmidt A., Altach E., Eggert V., Sommer C.J., Schäbitz W.R. Citicoline enhances neuroregenerative processes after experimental stroke in rats. Stroke 2012, 43:1931-1940.
14. Fragoso-Loyo H., Cabiedes J., Orozco-Narváez A., Dávila-Maldonado L., Atisha-Fregoso Y., Diamond B., Llorente L., Sánchez-Guerrero J. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS ONE 2008, 3:e3347.
15. Frauenknecht K., Plaschke K., Sommer C. Transient oligemia is associated with long-term changes in binding densities of cortical inhibitory GABAA receptors in the rat brain. Brain Res. 2009, 1271:95-102.
16. Frauenknecht K., Katzav A., Grimm C., Chapman J., Sommer C.J. Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors. Immunobiology 2013, 218:517-526.
17. Freedman R., Adler L.E., Bickford P., Byerley W., Coon H., Cullum C.M., Griffith J.M., Harris J.G., Leonard S., Miller C., et al. Schizophrenia and nicotinic receptors. Harv. Rev. Psychiatry 1994, 2:179-192.
18. Galli M., Barbui T., Zwaal R.F., Comfurius P., Bevers E.M. Antiphospholipid antibodies: involvement of protein cofactors. Haematologica 1993, 78:1-4.
19. Giannakopoulos B., Krilis S.A. The pathogenesis of the antiphospholipid syndrome. N. Engl. J. Med. 2013, 368:1033-1044.
20. Gómez-Puerta J.A., Cervera R., Calvo L.M., Gómez-Ansón B., Espinosa G., Claver G., Bucciarelli S., Bové A., Ramos-Casals M., Ingelmo M., Font J. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology (Oxford) 2005, 44:95-99.
21. Gulledge A.T., Bucci D.J., Zhang S.S., Matsui M., Yeh H.H. M1 receptors mediate cholinergic modulation of excitability in neocortical pyramidal neurons. J. Neurosci. 2009, 29:9888-9902.
22. Harbaugh R.E., Roberts D.W., Coombs D.W., Saunders R.L., Reeder T.M. Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease. Neurosurgery 1984, 15:514-518.
23. Harris E.N., Englert H., Derve G., Hughes G.R., Gharavi A. Antiphospholipid antibodies in acute Guillain-Barre syndrome. Lancet 1983, 2:1361-1362.
24. Hughes G.R. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br. Med. J. 1983, 287:1088-1089.
25. Hughes G.R. The anticardiolipin syndrome. Clin. Exp. Rheumatol. 1985, 3:285-286.
26. Hughes G.R. Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad. Med. J. 2003, 79:81-83.
27. Hughes G.R., Harris E.N., Gharavi A.E. The anticardiolipin syndrome. J. Rheumatol. 1986, 13:486-489.
28. Katzav A., Pick C.G., Korczyn A.D., Oest E., Blank M., Shoenfeld Y., Chapman J. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
29. Katzav A., Litvinjuk Y., Pick C.G., Blank M., Shoenfeld Y., Sirota P., Chapman J. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav. Brain Res. 2006, 169:289-293.
30. Katzav A., Shoenfeld Y., Chapman J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 2010, 38:196-200.
31. Katzav A., Kivity S., Blank M., Shoenfeld Y., Chapman J. Adjuvant immunization induces high levels of pathogenic antiphopholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus 2012, 21:210-216.
32. Katzav A., Grigoriadis N.C., Ebert T., Toulomi O., Blank M., Pick C.G., Shoenfeld Y., Chapman J. Coagulopathy triggered autoimmunity: experimental antiphospholipid syndrome in factor V Leiden mice. BMC Med. 2013, 11:92.
33. Kent M., Alvarez F., Vogt E., Fyffe R., Ng A.K., Rote N. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J. Rheumatol. 1997, 24:1725-1733.
34. Kent M.N., Alvarez F.J., Ng A.K., Rote N.S. Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain. Exp. Neurol. 2000, 163:173-179.
35. Kowal C., DeGiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., Diamone B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19854-19859.
36. Lee J.Y., Huerta P.T., Zhang J., Kowal C., Bestini E., Volpe B.T., Diamone B. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat. Med. 2009, 15:91-96.
37. Liou H.H., Wang C.R., Chen C.J., Chen R.C., Chuang C.Y., Chiang I.P., Tsai M.C. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996, 5:307-312.
38. Menachem A., Chapman J., Katzav A. Significant changes in the levels of secreted cytokines in brains of experimental antiphospholipid syndrome mice. Autoimmune Dis. 2012, 2012:404815.
39. Minzenberg M.J., Poole J.H., Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 2004, 161:116-124.
40. Mosek A., Yust I., Treves T.A., Vardinon N., Korczyn A.D., Chapman J. Dementia and antiphospholipid antibodies. Dement. Geriatr. Cogn. Disord. 2000, 11:36-38.
41. Müller H.D., Hanumanthiah K.M., Diederich K., Schwab S., Schäbitz W.R., Sommer C. Brain-derived neurotrophic factor but not forced arm use improves long-term outcome after photothrombotic stroke and transiently upregulates binding densities of excitatory glutamate receptors in the rat brain. Stroke 2008, 39:1012-1021.
42. Muscal E., Brey R.L. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus 2010, 19:406-411.
43. Paxinos G., Franklin K.J.B. The Mouse Brain in Stereotaxic Coordinates 2001, Academic, San Diego, Calif./London, c2001. 2nd ed.
44. Perry E., Walker M., Grace J., Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 1999, 22:273-280.
45. Rand J.H. Molecular pathogenesis of the antiphospholipid syndrome. Circ. Res. 2002, 90:29-37.
46. Roubey R.A., Pratt C.W., Buyon J.P., Winfield J.B. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J. Clin. Invest. 1992, 90:1100-1104.
47. Sanna G., Bertolaccini M.L., Cuadrado M.J., Laing H., Khamashta M.A., Mathieu A., Hughes G.R. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 2003, 30:985-992.
48. Sanna G., DCruz D., Cuadrado M.J. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum. Dis. Clin. N. Am. 2006, 32:465-490.
49. Schmidt R., Auer-Grumbach P., Fazekas F., Offenbacher H., Kapeller P. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke 1995, 26:749-754.
50. Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R., Beilin O., Pick C.G., Leider-Trejo L., Kalashnikova L., Blank M., Chapman J. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
51. Shoenfeld Y., Lev S., Blatt I., Blank M., Font J., von Landenberg P., Lev N., Zaech J., Cervera R., Piette J.C., Khamashta M.A., Bertolaccini M.L., Hughes G.R., Youinou P., Meroni P.L., Pengo V., Alves J.D., Tincani A., Szegedi G., Lakos G., Sturfelt G., Jönsen A., Koike T., Sanmarco M., Ruffatti A., Ulcova-Gallova Z., Praprotnik S., Rozman B., Lorber M., Chapman J., van-Breda-Vriezman P.J., Damoiseaux J. Features associated with epilepsy in the antiphospholipid syndrome. J. Rheumatol. 2004, 31:1344-1348.
52. Shrot S., Katzav A., Korczyn A.D., Litvinjuk Y., Hershenson R., Pick C.G., Blank M., Zaech J., Shoenfeld Y., Sirota P., Chapman J. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002, 11:736-743.
53. A receptors is upregulated in CA1 neurons of the gerbil hippocampus in the ischemia tolerant state. Stroke 2002, 33:1698-1705.
54. Tanne D., Hassin-Baer S. Neurologic manifestation of the antiphospholipid syndrome. Curr. Rheumatol. Rep. 2001, 3:286-292.
55. Verrot D., San-Marco M., Dravet C., Genton P., Disdier P., Bolla G., Harle J.R., Reynaud L., Weiller P.J. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am. J. Med. 1997, 103:33-37.
56. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu. Rev. Pharmacol. Toxicol. 2004, 44:423-450.
57. Wess J., Eglen R.M., Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug. Discov. 2007, 6:721-733.
58. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., Brey R., Derksen R., Harris E.N., Hughes G.R., Triplett D.A., Khamashta M.A. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999, 42:1309-1311.
59. Zilles K., Wu J., Crusio W.E., Schwegler H. Water maze and radial maze learning and the density of binding sites of glutamate, GABA, and serotonin receptors in the hippocampus of inbred mouse strains. Hippocampus 2000, 10:213-225.
60. Zilles K., Palomero-Gallagher N., Schleicher A. Transmitter receptors and functional anatomy of the cerebral cortex. J. Anat. 2004, 205:417-432.